RegeneRx Biopharmaceuticals, Inc.: Revision history

20 August 2022

• curprev 15:1915:19, 20 August 2022 95.149.241.133 talk 903 bytes +11 No edit summary undo

13 August 2022

• curprev 23:1523:15, 13 August 2022 109.180.50.163 talk 892 bytes +15 No edit summary undo

31 July 2022

• curprev 00:2900:29, 31 July 2022 >Chris 877 bytes +877 Created page with "RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other m..."